Ginkgo Bioworks Holdings (DNA) Operating Expenses (2020 - 2026)

Ginkgo Bioworks Holdings' Operating Expenses history runs 7 years deep, the most recent figure standing at $90.8 million for Q1 2026.

• Quarterly Operating Expenses fell 23.79% year-over-year to $90.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $439.0 million (down 36.38% YoY) and the FY2025 annual result came in at $485.4 million, down 38.3% from the prior year.
• Operating Expenses was $90.8 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $104.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $843.8 million in Q1 2022 and bottomed at $90.8 million in Q1 2026.
• A 5-year average of $302.8 million and a median of $215.9 million in 2024 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 733.67% in 2022, while the deepest fall reached 82.05% in 2022.
• Ginkgo Bioworks Holdings' Operating Expenses stood at $329.1 million in 2022, then plunged by 35.33% to $212.9 million in 2023, then plunged by 30.73% to $147.5 million in 2024, then dropped by 29.37% to $104.1 million in 2025, then fell by 12.77% to $90.8 million in 2026.
• Business Quant data shows DNA's Operating Expenses at $90.8 million in Q1 2026, $104.1 million in Q4 2025, and $128.9 million in Q3 2025.